Huang Christine, Noirot Laura A, Reichley Richard M, Bouselli Dennis A, Dunagan Wm Claiborne, Bailey Thomas C
BJC HealthCare, St. Louis, Missouri, USA.
AMIA Annu Symp Proc. 2005;2005:989.
Due to increasing reports of spironolactone associated life-threatening hyperkalemia, we implemented a rule in our automated event detection system to monitor serum potassium results in patients receiving spironolactone. In 2004, 419 (10.49%) of 3995 admissions at 3 BJC HealthCare hospitals were identified as having hyperkalemia while on spironolactone. For a 9-month period in one facility, 33 of 52 automatically detected potential ADEs had been validated by pharmacists through manual chart review to have spironolactone as a contributing factor (PPV=63.5%).
由于螺内酯相关的危及生命的高钾血症报告不断增加，我们在自动事件检测系统中实施了一项规则，以监测接受螺内酯治疗患者的血清钾结果。2004年，在BJC医疗保健系统的3家医院的3995例住院患者中，有419例（10.49%）在服用螺内酯时被确定患有高钾血症。在一个机构的9个月期间，药剂师通过人工病历审查验证了52例自动检测到的潜在药物不良反应中有33例将螺内酯作为一个促成因素（阳性预测值=63.5%）。
